A Phase 3b Study of Subjects With Alzheimer's Disease Who Discontinued Treatment in Bapineuzumab Phase 3 Clinical Studies (ELN115727-301/302/351) or Who Completed Studies ELN15727-301 and 302 But Did Not Enroll in Study ELN115727-351

Trial Profile

A Phase 3b Study of Subjects With Alzheimer's Disease Who Discontinued Treatment in Bapineuzumab Phase 3 Clinical Studies (ELN115727-301/302/351) or Who Completed Studies ELN15727-301 and 302 But Did Not Enroll in Study ELN115727-351

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 04 Sep 2015

At a glance

  • Drugs Bapineuzumab (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms RAPID
  • Sponsors JANSSEN Alzheimer Immunotherapy
  • Most Recent Events

    • 24 Aug 2012 Planned end date (Sep 2012) added as reported by ClinicalTrials.gov.
    • 24 Aug 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 14 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top